Douglas Lane & Associates LLC Purchases 26,014 Shares of Illumina, Inc. $ILMN

Key Points

• Douglas Lane & Associates LLC boosted its Illumina stake by 8.5% in Q4, buying 26,014 shares to hold 333,623 shares worth about $43.8 million (≈0.22% of the company).
• Illumina beat Q4 estimates with $1.35 EPS on $1.16B revenue and set FY2026 guidance of 5.050–5.200 EPS, but analyst coverage is mixed—consensus is a Hold with an average price target of $129.69, even as some firms raised targets (Guggenheim $170).
• Institutional ownership is high at 89.42%; insiders have recently sold shares (SVP Patricia Leckman sold 2,370 shares), and Illumina has a market cap of roughly $18.9B and a PE of about 22.7.

Douglas Lane & Associates LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 8.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 333,623 shares of the life sciences company's stock after purchasing an additional 26,014 shares during the quarter. Douglas Lane & Associates LLC owned about 0.22% of Illumina worth $43,758,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Board of the Pension Protection Fund acquired a new position in shares of Illumina during the 4th quarter worth about $26,000. Quent Capital LLC acquired a new position in shares of Illumina during the 3rd quarter worth about $29,000. Quarry LP acquired a new position in shares of Illumina during the 3rd quarter worth about $32,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Illumina during the 3rd quarter worth about $33,000. Finally, Flagship Harbor Advisors LLC acquired a new position in shares of Illumina during the 4th quarter worth about $33,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ILMN shares. Guggenheim boosted their target price on Illumina from $144.00 to $170.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. Robert W. Baird set a $137.00 target price on Illumina in a research report on Friday, February 6th. Canaccord Genuity Group boosted their target price on Illumina from $130.00 to $150.00 and gave the stock a "hold" rating in a research report on Monday, January 26th. Wall Street Zen upgraded Illumina from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 14th. Finally, Evercore set a $150.00 target price on Illumina in a research report on Friday, February 6th. Six research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Illumina currently has an average rating of "Hold" and a consensus price target of $129.69.

Illumina Price Performance

Shares of ILMN opened at $123.67 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The stock has a 50 day simple moving average of $124.43 and a 200 day simple moving average of $123.15. Illumina, Inc. has a 52-week low of $69.29 and a 52-week high of $155.53. The firm has a market capitalization of $18.91 billion, a PE ratio of 22.69, a P/E/G ratio of 2.45 and a beta of 1.49.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period in the previous year, the firm earned $0.95 EPS. Illumina's quarterly revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Activity at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the business's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.60% of the stock is currently owned by company insiders.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.